A novel class of Na+ and Ca2+ channel dual blockers with highly potent anti-ischemic effects

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 20, 1999, Pages 2999-3002

  Annoura, Hirokazu ^a   Nakanishi, Kyoko ^a   Uesugi, Mayumi ^a   Miyajima, Atsuko Fukunaga Atsuko ^a   Tamura Horikawa, Yoshiko ^a   Tamura, Shigeki ^a  

^a SUNTORY LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 3 PHENOXY)PROPYL 4 (4 PHENOXYPHENYL) PIPERIDINE; CALCIUM; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DOPAMINE RECEPTOR; FLUNARIZINE; PIPERIDINE DERIVATIVE; SODIUM; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; DRUG SCREENING; DRUG SYNTHESIS; NONHUMAN; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; EPILEPSY, REFLEX; ISCHEMIC ATTACK, TRANSIENT; MICE; MICE, INBRED DBA; NEUROPROTECTIVE AGENTS; PHENYL ETHERS; PIPERIDINES; SODIUM CHANNEL BLOCKERS;

ANIMALIA;

EID: 0033581626     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00516-8     Document Type: Article

References (28)

1. For reviews: (a) Farber, J. L.; Life Sciences 1981, 29, 1289;
2. (b) Meyer, F. B.; Brain Research Reviews 1989, 14, 227;
3. (c) Choi, D. W.; Trends Neurosci. 1995, 18, 58;
4. (d) Kristiàn T.; Siesjö, B. K.; Life Sciences 1996, 59, 357;
5. (e) idem;
6. Stroke 1998, 29, 705.
7. For reviews: (a) Boddeke, E.; Hugtenburg, J.; Jap, W.; Heynis, J.; Van Zwieten, P.; Trends Pharmacol. Sci. 1989, 10, 397;
8. (b) Pauwels, P. J.; Leysen, J. E.; Janssen, P. A. J.; Life Sciences 1991, 48, 1881;
9. (c) Urenjak, J.; Obrenovitch, T. P.; Pharmacological Reviews, 1996, 48, 21.
10. (a) Alps, B. J.; Calder, C.; Hass, W. K.; Wilson, A. D.; Br. J. Pharmacol. 1988, 93, 877;
11. (b) Gotti, B.; Benavides, J.; MacKenzie, E. T.; Scatton, B.; Brain Research 1990, 522, 290;
12. (c) De Ryck, M.; Eur. Neurol. 1990, 30 (Suppl. 2), 21;
13. (d) Peters, Th.; Wilffert, B.; Vanhoutte, P. M.; Van Zwieten, P. A.; J. Cardiovasc. Pharmcol. 1991, 18 (Suppl. 8), S1;
14. (e) Takahashi, K.; Akaike, N.; J. Pharma. Exp. Ther. 1991, 256, 169.
15. Brown, C. M.; Calder, C.; Alps, B. J.; Spedding, M.; Br. J. Pharmacol. 1993, 109, 175.
16. Ito, C.; Im, W. B.; Takagi, H.; Takahashi, M.; Tsuzuki, K.; Liou, S.-Y.; Kunihara, M.; Eur. J. Pharmacol. 1994, 203.
17. 2+ ions under pathological, ischemic conditions: (a) Van Zwieten, P. A.; Arzneim.-Forsch. 1985, 35, 298;
18. 2+ ions under pathological, ischemic conditions: (a) Van Zwieten, P. A.; Arzneim.-Forsch. 1985, 35, 298;
19. (b) idem; Eur. Neurol. 1986, 25 (Suppl. 1), 57.
20. For reviews: (a) Montastruc, J. L.; Llau, M. E.; Rascol, O.; Senard, J. M.; Fundam. Clin. Pharmacol. 1994, 8, 293;
21. (b) Daniel, J. R.; Mauro, V. F.; Ann. Pharmacother. 1995, 29, 73.
22. Perez-Reyes, E.; Cribbs, L. L.; Daud, A.; Lacerda, A. E.; Barclay, J.; Williamson, M. P.; Fox, M.; Rees, M.; Lee, J.-H.; Nature, 1998, 391, 896; See also ref. 2b, 3d, e and 5 in relation to ischemic cell death.
23. 3SiH in trifluoroacetic acid in 82% overall yield. Satisfactory spectroscopic data were obtained for all new compounds.
24. Aiuchi, T.; Matsunaga, M.; Daimatsu, T.; Nakaya, K.; Nakamura, Y.; Biochimi. Biophys. Acta 1984, 771, 228.
25. Kohler, C.; Hall, H.; Ogren, S. O.; Gawell, L.; Biochem. Pharmacol. 1985, 34, 2251.
26. (a) De Sarro, G. B.; Meldrum, B. S.; Nisticò, G.; Br. J. Pharmacol. 1988, 93, 247;
27. (b)Eigyo, M.; Shiomi, T.; Inoue, Y.; Sakaguchi, I.; Ishibashi, C.; Murata, S.; Koyabu, K.; Matsushita, A.; Adachi, I.; Ueda, M.; Jpn. J. Pharmacol. 1994, 65, 175.
28. Koizumi J.; Yoshida Y.; Nakazawa T.; Ooneda G.; Jpn. J. Stroke 1986, 8, 1.